To control antibody mediated rejection following kidney and liver transplantation in ABO-incompatible, donor specific antibody positive patients by using rituximab, proteasome inhibitor, complement inhibitor, and immunoglobulin administration

To control antibody mediated rejection following kidney and liver transplantation in ABO-incompatible, donor specific antibody positive patients by using rituximab, proteasome inhibitor, complement inhibitor, and immunoglobulin administration - Management for antibody mediated rejection

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000023064

Enrollment

200

Registered

2016-09-01

Start date

2016-07-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Antibody mediated rejection

Interventions

Rituximab 375mg/m2 before (prophylaxis) or after surgery (treatment), Proteasome inhibitors 1.3mg/m2 at a time of confirming antibody mediated rejection following surgery, complement inhibitors (ecul

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Organ transplantation recipients who are treated in our hospital

Exclusion criteria

Exclusion criteria: Cases who has allergic reaction against relevant drugs.

Design outcomes

Primary

Measure	Time frame
Judging improvements of clinical (Cr, AST, ALT, T-Bil etc.) and pathological findings(Banff 2013 criteria) at day 1, 3, 5, 7, 14, 28, and during a follow-up period following administration.	—

Countries

Japan

Contacts

Public ContactShumpei Harada

Kyoto Prefectural University of Medicine Organ Transplantation and Regenerative Surgery

shumpei@koto.kpu-m.ac.jp81752515532

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026